NEW YORK (GenomeWeb News) – Decode Genetics said today that it has licensed three genetic markers for cardiovascular and metabolic diseases to Celera.

The markers may be used to create lab tests for individual risks of heart attack, stroke, atrial fibrillation, and type 2 diabetes, Decode said.

Under the agreement, Decode will receive an upfront payment and royalties from sales of testing products that use the markers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.